Insider Selling CRISPR Therapeutics AG CEO Sells 15,000 Shares of Stock
| CRSP Stock | USD 40.94 0.46 1.14% |
Slightly above 52% of Crispr Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Crispr Therapeutics AG suggests that many traders are impartial. Crispr Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Crispr Therapeutics AG. Many technical investors use Crispr Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Crispr |
CRISPR Therapeutics AG CEO Samarth Kulkarni sold 15,000 shares of the businesss stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of 55.10, for a total value of 826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company,
Read at thelincolnianonline.com
 |
Crispr Therapeutics Current Investor Sentiment
Panic Vs Confidence
48
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Crispr Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Crispr Therapeutics AG.
News SentimentNeutral | Hype SentimentNeutral | Insider SentimentDisposing |
Crispr Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Crispr Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Crispr Therapeutics Historical Investor Sentiment
Investor biases related to Crispr Therapeutics' public news can be used to forecast risks associated with an investment in Crispr. The trend in average sentiment can be used to explain how an investor holding Crispr can time the market purely based on public headlines and social activities around Crispr Therapeutics AG. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Crispr Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Crispr Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Crispr Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Crispr Therapeutics.
Crispr Therapeutics Fundamental Analysis
We analyze Crispr Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crispr Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crispr Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Crispr Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Crispr Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Crispr Therapeutics stock to make a market-neutral strategy. Peer analysis of Crispr Therapeutics could also be used in its relative valuation, which is a method of valuing Crispr Therapeutics by comparing valuation metrics with similar companies.
Peers
Crispr Therapeutics Related Equities
| NVO | Novo Nordisk | 4.36 | ||||
| HEPA | Hepion Pharmaceuticals | 2.04 | ||||
| REGN | Regeneron Pharmaceuticals | 1.89 | ||||
| SRPT | Sarepta Therapeutics | 1.03 | ||||
| BEAM | Beam Therapeutics | 0.38 | ||||
| NTLA | Intellia Therapeutics | 0.66 | ||||
| FATE | Fate Therapeutics | 1.19 | ||||
| VERV | Verve Therapeutics | 2.20 | ||||
| KRYS | Krystal Biotech | 2.43 | ||||
| EDIT | Editas Medicine | 3.20 | ||||
| CRBU | Caribou Biosciences | 5.59 |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.